#43 How to leverage past experience in developing treatments for rare disease. James Mackay, PhD - CEO, Aristea Therapeutics

This episode of BioTech IQ features James Mackay, PhD, Founder and CEO of Aristea Therapeutics. Aristea Therapeutics is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. In particular, their lead asset is addressing palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States that affects about 100,000 people.Don't miss this episode as we discuss James' background and the strategy of Aristea's approach to their current asset.https://aristeatx.com/Check out out more episodes at https://thebiotechiqpodcast.com/Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/